Skip to main content

Advertisement

SpringerLink
Log in

Chimlothéraple du cancer colorectal et intensification

Dose intensification with irinotecan in colorectal cancer

  • Published:
Acta Endoscopica

Résumé

Les nouvelles molécules de chimiothérapie ont apporté un bénéfice dans le traitement des formes métastatiques de cancer colorectal en termes de réponse et de survie. Il est cependant possible dans certaines situations cliniques d'augmenter encore le pourcentage de réponse en intensifiant la chimiothérapie. Ceci est particulièrement vrai avec les combinaisons à base d'irinotécan qui peut être donné à plus fortes doses. L'autre moyen d'intensifier la chimiothérapie des cancers colorectaux métastasés est d'utiliser des protocoles de trithérapie combinant 5FU, acide folinique, irinotécan et oxaliplatine. Les résultats de ces différentes approches sont prometteurs avec de l'ordre de 70% d réponses objectives et 95 à 100% de contrôle tumoral.

Summary

The new developments of chemotherapy in colorectal cancer have shown that it was possible with new drugs to increase response rate and survival of the patients. It has been shown that it was possible to treat some patients with surgery after response to therapy. Considering this aim of treatment it seems important to increase more and more the response rate to chemotherapy. This seems possible with new schedules of chemotherapy. With irinotecan based regimens, there are two ways to intensify the treatment. The first one is to increase the doses of irinotecan combined with 5 FU, and the other one is to combine the three major agents of chemotherapy of colorectal cancer leading to the concept of three therapy. These news approaches give high response rate up to 75% and in 95 to 100% of tumour growth control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. ABIGERGES D., CHABOT G.G., ARMAND J.P., HERAIT P., GOUYETTE A., GANDIA D. — Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.J. Clin. Oncol., 1995,13, 210–221.

    PubMed  CAS  Google Scholar 

  2. MERROUCHE Y., EXTRA J.M., ABIGERGES D., BUGAT R., CATIMEL G., SUC E.et al. — High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.J. Clin. Oncol., 1997,75, 1080–1086.

    Google Scholar 

  3. van CUTSEM E., DIRIX L., Van LAETHEM J., Van BELLE S., BORNER M., GONZALES M.et al. — A randomized phase II trial of three different regimens of irinotecan (CPT11): a fixed dose of 350 mg/m2 (A), or an individual dose optimisation (B) or a risk factor optimisation (C) in patients (Pts) with metastatic colorectal cancer (MCRC) previously treated with 5FU.Proc. Am. Soc. Clin. Oncol., 2000,19, 244a.

    Google Scholar 

  4. YCHOU M., KRAMAR A., RAOUL J.-L., DESSEIGNE F., HUA A., VERNILLET L.et al. — Final results of a phase II study using CPT-11 high dose (500 mg/m2) as first line chemotherapy in patients with metastatic colorectal cancer (MCRC).Proc. Am. Soc. Clin. Onc., 2000,19, 249a.

    Google Scholar 

  5. DUCREUX M., YCHOU M., SEITZ J.-F., BONNAY M., BEXON A., ARMAND J.-P.et al. — Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.J. Clin. Oncol., 1999,17, 2901–2908.

    PubMed  CAS  Google Scholar 

  6. DUCREUX M., RAOUL J.-L., MARTI P., MERROUCHE Y., TIGAUD J.-M., RISSE M.-L.et al. — Irinotecan (CPT-11) high-dose 260 mg/m2 with 5-FU/FA (LV5FU2 or LV5FUS) in 1st line metastatic colorectal cancer (MCRC). Phase II study.Proc. Am. Soc. Clin. Onc., 2002,21, 160a.

    Google Scholar 

  7. CONROY T., SEITZ J.-F., CAPODANO G., KRAMAR A., HUA A., YCHOU M. — Phase I study of triple combination of oxaliplatin + irinotecan + Lv5fu2 in patients with metastatic solid tumors.Proc. Am. Soc. Clin. Onc., 2000,19, 236a.

    Google Scholar 

  8. YCHOU M., NORDLINGER B., QUENET F., RIVOIRE M., DESSEIGNE F., NEGRIER S.et al. — CPT-11/L-OHP/5-FU/LV combination before liver surgery in patients with not optimally resectable colorectal cancer liver metastases: methodology and preliminary results, phase II study.Proc. Am. Soc. Clin. Onc., 2002,21, 162a.

    Google Scholar 

  9. FALCONE A., MASI G., ALLEGRINI G., DANESI R., PFANNER E., BRUNETTI I.M.et al. — Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.J. Clin. Oncol., 2002,20, 4006–4014.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de Gastroentérologie, Institut Gustave Roussy, rue Camille-Desmoulins, 94805, Villejuif Cedex, (France)

    M. Ducreux & Valérie Boige

Authors
  1. M. Ducreux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valérie Boige
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Ducreux, M., Boige, V. Chimlothéraple du cancer colorectal et intensification. Acta Endosc 32, 683–689 (2002). https://doi.org/10.1007/BF03018875

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03018875

Mots-clés

Key-words

Search

Navigation